PhaseBio Pharmaceuticals, Inc. (PHAS) |
|
0.0701 0 (0%)
|
11-02 16:00 |
|
Open: |
0.0807 |
Pre. Close: |
0.0701 |
|
High:
|
0.092 |
Low:
|
0.0665 |
|
Volume:
|
8,603,716 |
Market Cap:
|
0(M) |
|
|
|
Technical analysis |
as of: 2023-01-06 4:33:43 PM |
|
Short-term rate:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 0.11  One year: 0.16 |
| Support: |
Support1: 0.04 Support2: 0.03 |
| Resistance: |
Resistance1: 0.1 Resistance2: 0.13 |
| Pivot: |
0.05  |
| Moving Average: |
MA(5): 0.04 MA(20): 0.06
MA(100): 0.59 MA(250): 1.03 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 5.1 %D(3): 4.5 |
| RSI: |
RSI(14): 32 |
| 52-week: |
High: 2.7 Low: 0.04 |
| Average Vol(K): |
3-Month: 2,069 (K) 10-Days: 369 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PHAS ] has closed above bottom band by 38.0%. Bollinger Bands are 75.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 37 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.05 - 0.05 |
0.05 - 0.05 |
|
Low:
|
0.04 - 0.04 |
0.04 - 0.04 |
|
Close:
|
0.05 - 0.05 |
0.05 - 0.05 |
|
Company Description |
|
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. |
Headline News |
Thu, 05 Jan 2023
Bankruptcy court approves PhaseBio's $32.9M asset transfer deal - The Business Journals
Mon, 24 Oct 2022
PhaseBio Plans for Near-Term Sale Using Structured Process ... - Business Wire
Thu, 29 Sep 2022
Why an East Bay company wants control of its partner's blood ... - The Business Journals
Mon, 16 May 2022
PhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for ... - Business Wire
Mon, 04 Apr 2022
PhaseBio Announces Positive Results from Phase 2b Trial for ... - Business Wire
Tue, 08 Mar 2022
PhaseBio Pharmaceuticals Announces Bentracimab Manufacturing ... - BioSpace
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
50 (M) |
|
% Held by Insiders
|
3.441e+007 (%) |
|
% Held by Institutions
|
6.7 (%) |
|
Shares Short
|
1,470 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.0226e+008 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-12 |
|
Return on Assets (ttm)
|
738.6 |
|
Return on Equity (ttm)
|
-106.1 |
|
Qtrly Rev. Growth
|
818000 |
|
Gross Profit (p.s.)
|
-34.15 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-3.18049e+007 |
|
Qtrly Earnings Growth
|
-2.4 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-59 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.06 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
2.07e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
